New cream may ease skin symptoms in rare autoimmune disease
NCT ID NCT06857240
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This study tests a cream called ruxolitinib for skin symptoms in people with dermatomyositis, a rare autoimmune disease. The cream is applied directly to the skin. Researchers will check if it is safe and reduces skin activity after 8 and 12 weeks. The study involves 15 adults whose skin symptoms have not improved with other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact
Conditions
Explore the condition pages connected to this study.